论文部分内容阅读
自1981年5月对山东莱阳生化制药厂和山东医学院研制的胸腺素注射液进行鉴定后,又对157例病人进行验证,亦取得了较好疗效,现总结报告于下。一、病例选择及疗效标准本组病例均按全国有关会议制定标准及“山东省四厅胸腺素协作组济南会议”所制定的标准选择。疗效标准亦按上述原则确定。二、药物及用法本组病人所用胸腺素均由山东莱阳生化制药厂提供,用量根据不同病种及年龄,分别为5～10mg肌肉或皮下注射,一周二次,隔日一
Since May 1981, Shandong Laiyang Biochemical Pharmaceutical Factory and Shandong Medical University developed thymosin injection identification, and 157 patients were validated, but also achieved good results, are summarized in the report below. First, the case selection and efficacy standards The patients were selected according to the national standards for the development of the meeting and the “meeting of Shandong Province four thymosin collaboration group Jinan” standards. Efficacy standards are also determined according to the above principles. Second, the use of drugs and the use of thymosin in this group of patients by Shandong Laiyang biochemical pharmaceutical factory, dosage according to different diseases and age, respectively, 5 ~ 10mg muscle or subcutaneous injection, twice a week, every other day